<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898794</url>
  </required_header>
  <id_info>
    <org_study_id>KSGR-GR-01-07</org_study_id>
    <secondary_id>CDR0000631252</secondary_id>
    <nct_id>NCT00898794</nct_id>
  </id_info>
  <brief_title>Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer</brief_title>
  <official_title>Influence of Bevacizumab and VEGF on Platelet Aggregation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Graubuenden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.

      PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet
      clustering in patients with cancer who are receiving bevacizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the influence of bevacizumab on platelet aggregation in patients receiving
           bevacizumab for cancer.

        -  To determine the influence of VEGF on platelet aggregation.

        -  To determine the influence of VEGF or bevacizumab on cyclooxygenesis.

        -  To determine if the sequence of medication plays a role in platelet aggregation.

      OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are
      analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial
      activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble
      P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Anticipated">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Influence of bevacizumab on platelet aggregation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of VEGF on platelet aggregation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of VEGF or bevacizumab on cyclooxygenesis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between medication sequence and platelet aggregation</measure>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>coagulation study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>platelet aggregation test</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Receiving bevacizumab for cancer

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger von Moos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Graubuenden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger von Moos, MD</last_name>
      <phone>41-81-256-6646</phone>
      <email>roger.vonmoos@ksgr.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

